The New England journal of medicine, 2020-01, Vol.382 (2), p.120-129
- Dangas, George D
- Tijssen, Jan G.P
- Wöhrle, Jochen
- Søndergaard, Lars
- Gilard, Martine
- Möllmann, Helge
- Makkar, Raj R
- Herrmann, Howard C
- Giustino, Gennaro
- Baldus, Stephan
- De Backer, Ole
- Guimarães, Ana H.C
- Gullestad, Lars
- Kini, Annapoorna
- von Lewinski, Dirk
- Mack, Michael
- Moreno, Raúl
- Schäfer, Ulrich
- Seeger, Julia
- Tchétché, Didier
- Thomitzek, Karen
- Valgimigli, Marco
- Vranckx, Pascal
- Welsh, Robert C
- Wildgoose, Peter
- Volkl, Albert A
- Zazula, Ana
- van Amsterdam, Ronald G.M
- Mehran, Roxana
- Windecker, Stephan
2020
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Dangas, George D
- Tijssen, Jan G.P
- Wöhrle, Jochen
- Søndergaard, Lars
- Gilard, Martine
- Möllmann, Helge
- Makkar, Raj R
- Herrmann, Howard C
- Giustino, Gennaro
- Baldus, Stephan
- De Backer, Ole
- Guimarães, Ana H.C
- Gullestad, Lars
- Kini, Annapoorna
- von Lewinski, Dirk
- Mack, Michael
- Moreno, Raúl
- Schäfer, Ulrich
- Seeger, Julia
- Tchétché, Didier
- Thomitzek, Karen
- Valgimigli, Marco
- Vranckx, Pascal
- Welsh, Robert C
- Wildgoose, Peter
- Volkl, Albert A
- Zazula, Ana
- van Amsterdam, Ronald G.M
- Mehran, Roxana
- Windecker, Stephan
- Titel
- A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement
- Ist Teil von
- The New England journal of medicine, 2020-01, Vol.382 (2), p.120-129
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2020
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Patients who had undergone successful TAVR were randomly assigned to receive either a rivaroxaban-based antithrombotic regimen or an antiplatelet-based antithrombotic regimen. At 17 months, the primary outcome of death or thromboembolic complications occurred more frequently with rivaroxaban.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793, 1533-4406eISSN: 1533-4406DOI: 10.1056/NEJMoa1911425Titel-ID: cdi_liege_orbi_v2_oai_orbi_ulg_ac_be_2268_290878
- Format
- –
- Schlagworte
- 9NDF7JZ4M3 (Rivaroxaban), A74586SNO7 (Clopidogrel), Aged, Aged, 80 and over, Aspirin, Aspirin - adverse effects, Aspirin - therapeutic use, Aspirin/adverse effects/therapeutic use, Atrial Fibrillation - drug therapy, Bleeding, Cardiac arrhythmia, Cardiovascular & respiratory systems, Cardiovascular Diseases - mortality, Clopidogrel, Clopidogrel - adverse effects, Clopidogrel - therapeutic use, Clopidogrel/adverse effects/therapeutic use, Confidence intervals, Death, Drug Therapy, Combination, Embolisms, Factor Xa Inhibitors, Factor Xa Inhibitors - adverse effects, Factor Xa Inhibitors - therapeutic use, Factor Xa Inhibitors/adverse effects/therapeutic use, Female, Heart Valve Prosthesis, Hemorrhage - chemically induced, Human health sciences, Humans, Intention to Treat Analysis, Kaplan-Meier Estimate, Male, Platelet Aggregation Inhibitors, Platelet Aggregation Inhibitors - adverse effects, Platelet Aggregation Inhibitors - therapeutic use, Platelet Aggregation Inhibitors/adverse effects/therapeutic use, R16CO5Y76E (Aspirin), Rivaroxaban - adverse effects, Rivaroxaban - therapeutic use, Rivaroxaban/adverse effects/therapeutic use, Safety, Sciences de la santé humaine, Statistical analysis, Systèmes cardiovasculaire & respiratoire, Thromboembolism, Thromboembolism - mortality, Thrombosis, Transcatheter Aortic Valve Replacement